anti-ror1 antibody-drug conjugate im-1021
Generic: Anti-ROR1 Antibody-drug Conjugate IM-1021
anti-ror1 antibody-drug conjugate im-1021: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Immunome Inc. (IMNM) | Phase 1 |
Clinical Trials (1)
A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies
Frequently asked questions
Who is developing anti-ror1 antibody-drug conjugate im-1021?
anti-ror1 antibody-drug conjugate im-1021 is being developed by Immunome Inc..
How many clinical trials involve anti-ror1 antibody-drug conjugate im-1021?
BioSniper tracks 1 clinical trial involving anti-ror1 antibody-drug conjugate im-1021.
Get deeper analysis on anti-ror1 antibody-drug conjugate im-1021
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis